Myriam Labopin Selected Research

Antilymphocyte Serum (Anti-Thymocyte Globulin)

1/2022	Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
1/2021	Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
1/2021	Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia.
12/2020	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.
1/2020	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.
1/2020	Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin.
1/2020	Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.
1/2020	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.
12/2019	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.
1/2019	Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Myriam Labopin Research Topics

Disease

160	Leukemia 10/2022 - 04/2002
144	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 11/2002
46	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2022 - 02/2004
42	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2022 - 02/2008
16	Neoplasms (Cancer) 03/2021 - 03/2015
13	Pathologic Complete Response 10/2022 - 11/2010
9	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 02/2010
8	Hematologic Neoplasms (Hematological Malignancy) 08/2020 - 02/2006
7	Bronchiolitis Obliterans Syndrome 11/2021 - 05/2015
5	Residual Neoplasm 12/2020 - 09/2014
5	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 07/2008
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2019 - 09/2014
5	Crohn Disease (Crohn's Disease) 05/2019 - 12/2015
4	Hematologic Diseases (Blood Diseases) 01/2021 - 01/2017
3	Philadelphia Chromosome 01/2021 - 03/2015
3	Infections 01/2020 - 09/2015
3	Sickle Cell Anemia (Hemoglobin S Disease) 12/2019 - 01/2017
2	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 10/2021 - 01/2018
2	COVID-19 01/2021 - 01/2021
2	Systemic Scleroderma (Systemic Sclerosis) 01/2021 - 12/2017
2	Monosomy 01/2020 - 01/2018
2	monosomy Chromosome 7 01/2020 - 01/2018
2	Inflammation (Inflammations) 05/2019 - 01/2017
1	Cardiotoxicity 06/2021
1	Acute Promyelocytic Leukemia 01/2021
1	Diffuse Scleroderma (Progressive Systemic Sclerosis) 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Hyperbilirubinemia 12/2020
1	Malnutrition (Nutritional Deficiencies) 11/2020
1	Sarcoma (Soft Tissue Sarcoma) 10/2020
1	Multiple Sclerosis 01/2020
1	Bites and Stings (Sting) 01/2020
1	Bone Marrow Failure Disorders 01/2020
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2020
1	Cytopenia 01/2020
1	Toxoplasmosis 01/2020
1	Immune System Diseases (Immune Disorders) 10/2019
1	Arthralgia (Joint Pain) 01/2019
1	Arthritis (Polyarthritis) 01/2019
1	Hemorrhage 01/2018

Drug/Important Bio-Agent (IBA)

45	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 10/2013
24	Busulfan (Busulfex)FDA Link 01/2022 - 10/2013
19	fludarabineIBA 01/2022 - 04/2015
17	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2022 - 05/2015
12	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 01/2022 - 01/2016
9	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 11/2008
6	treosulfanIBA 01/2022 - 07/2017
6	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 04/2015
5	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2022 - 03/2016
5	Tyrosine Kinase InhibitorsIBA 01/2021 - 03/2015
5	Clofarabine (Clolar)FDA Link 08/2020 - 09/2012
4	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 07/2008
4	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 05/2015
4	Calcineurin InhibitorsIBA 01/2021 - 03/2016
4	Sorafenib (BAY 43-9006)FDA Link 03/2019 - 01/2018
3	AntigensIBA 01/2022 - 05/2019
3	Azacitidine (5 Azacytidine)FDA Link 01/2020 - 01/2016
3	SteroidsIBA 01/2017 - 04/2002
2	fms-Like Tyrosine Kinase 3IBA 01/2022 - 01/2020
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 12/2019
2	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 12/2020
2	defibrotideIBA 10/2021 - 01/2018
2	Gemtuzumab (Mylotarg)FDA Link 12/2020 - 01/2020
2	AntibodiesIBA 01/2020 - 02/2015
2	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 01/2018
2	Interleukin-15 (Interleukin 15)IBA 04/2018 - 01/2018
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2016 - 02/2004
1	Alkylating AgentsIBA 01/2022
1	Amsacrine (AMSA)IBA 01/2022
1	Core Binding Factor Alpha 2 SubunitIBA 10/2021
1	Transaminases (Aminotransferases)IBA 12/2020
1	Tacrolimus (Prograf)FDA LinkGeneric 10/2020
1	antineoplaston A10 (A 10)IBA 01/2020
1	Core Binding Factors (Core-Binding Factor)IBA 01/2020
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2020
1	Rituximab (Mabthera)FDA Link 01/2020
1	Thymidine Monophosphate (TMP)IBA 01/2020
1	Phenobarbital (Luminal)FDA Link 05/2019
1	LigandsIBA 01/2019
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2019
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2018
1	Transcription Factors (Transcription Factor)IBA 01/2018
1	CohesinsIBA 01/2018
1	Polycomb Repressive Complex 2IBA 01/2018

Therapy/Procedure

151	Transplantation 10/2022 - 04/2002
115	Stem Cell Transplantation 10/2022 - 02/2003
74	Hematopoietic Stem Cell Transplantation 10/2022 - 11/2002
43	Cell Transplantation 10/2022 - 02/2015
31	Therapeutics 01/2021 - 04/2002
19	Haploidentical Transplantation 01/2022 - 04/2015
18	Drug Therapy (Chemotherapy) 01/2022 - 06/2008
12	Homologous Transplantation 01/2020 - 11/2002
11	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2022 - 04/2002
7	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 10/2022 - 03/2015
4	Autologous Transplantation 12/2017 - 01/2005
1	Cord Blood Stem Cell Transplantation 10/2022
1	Traction 01/2021
1	Nutritional Support (Artificial Feeding) 11/2020
1	Donor Selection 11/2019
1	Biological Therapy 05/2019